Valneva

Pfizer Invests in Valneva, Updates Lyme Vaccine Venture

Pfizer is to invest $95 million and take an equity share of 8.1% in in Valneva in order to further support development of a vaccine for Lyme disease.

EU May Cancel Valneva Covid Vaccine Order

The European Commission has indicated it may cancel an advance purchase agreement with Valneva that calls for the France-headquartered biotech to supply 60 million doses of its Covid-19 vaccine candidate over a two-year period up to 2023. A clause in the 2021 contract provided for termination if the European Medicines Agency (EMA) failed to grant conditional marketing authorization before the end of April 2022.

UK Cancels Valneva Covid Vaccine Contract

Three days after the UK canceled its vaccine supply contract with French drugmaker Valneva on Sept. 13, speculation was mounting that the European Commission might be prepared to take the 100 million doses Valneva was pledged to supply or even offer production facilities in an EU member state.

UK Signs Vaccine Deals With BioNTech and Valneva

The UK has signed an agreement to secure 90 million doses of Covid-19 vaccines developed by Germany’s BioNTech and France’s Valneva. The deals, for which financial terms were not disclosed, foresee taking 30 million doses from the German and 60 million from the French company.

Pharmaserv Logistics: Logistics services for Valneva